Rachel Vatnsdal
Stock Analyst at JP Morgan
(2.75)
# 1,217
Out of 4,413 analysts
12
Total ratings
44.44%
Success rate
0.41%
Average return
Main Sectors:
6 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PACB Pacific Biosciences of California | Downgrades: Neutral | n/a | $1.69 | - | 1 | Apr 22, 2024 | |
| HSIC Henry Schein | Maintains: Overweight | $82 → $88 | $68.78 | +27.94% | 2 | Mar 6, 2024 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $11 → $8 | $2.79 | +186.74% | 1 | Feb 15, 2024 | |
| DHR Danaher | Maintains: Overweight | $250 → $270 | $246.89 | +9.36% | 4 | Dec 20, 2023 | |
| MYGN Myriad Genetics | Maintains: Underweight | $17 → $14 | $19.47 | -28.09% | 2 | Nov 7, 2023 | |
| RVTY Revvity | Maintains: Neutral | $130 → $110 | $102.60 | +7.21% | 2 | Oct 17, 2023 |
Pacific Biosciences of California
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.69
Upside: -
Henry Schein
Mar 6, 2024
Maintains: Overweight
Price Target: $82 → $88
Current: $68.78
Upside: +27.94%
Adaptive Biotechnologies
Feb 15, 2024
Maintains: Overweight
Price Target: $11 → $8
Current: $2.79
Upside: +186.74%
Danaher
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $246.89
Upside: +9.36%
Myriad Genetics
Nov 7, 2023
Maintains: Underweight
Price Target: $17 → $14
Current: $19.47
Upside: -28.09%
Revvity
Oct 17, 2023
Maintains: Neutral
Price Target: $130 → $110
Current: $102.60
Upside: +7.21%